Effectiveness of beta-glucan supplementation to interleukine-6, interleukine-10 and tumour necrosis factor alpha in overweight and obese subject

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20140604001

Enrollment

Registered

2014-06-04

Start date

2014-06-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation Interleukin Tumour nacrosis factor

Interventions

Î²&#45

glucans ,Flour

Experimental Dietary Supplement,Placebo Comparator No treatment

Beta&#45

glucan,Flour

Eligibility

Sex/Gender

All

Age

21 Years to 65 Years

Inclusion criteria

Inclusion criteria: BMI more than 23 kg m2 Agree to maintain current lifestyle e g diet and exercise during the trial

Exclusion criteria

Exclusion criteria: -Major comorbidity e g CAD cancer -Major psychiatric disorders -Consumption of weigh loss products or actively attempting to loss weight -Pregnant or lactating females -Eating disorder or laxative abuse -Received or stopped using drug treatment on non communicable chronic diseases than 3 months -Lost body weight 5 kg during 6 months before starting experiment -Current or recent participant in another clinical trial 90 days

Design outcomes

Primary

Measure	Time frame
Inflammation 2 ELISA	—

Secondary

Measure	Time frame
General biochemical markers 2 Automated Analysis	—

Countries

Thailand

Contacts

Public ContactPattaneeya Prangthip

Department of Tropical Nutrition and Food Science

pattaneeya.pra@mahidol.ac.th023549100

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Effectiveness of beta&#45;glucan supplementation to interleukine&#45;6&#44; interleukine&#45;10 and tumour necrosis factor alpha in overweight and obese subject